Phaseline

Targets › ADRB2

ADRB2 (Beta-2 adrenergic receptor): drug programs, companies and trials

113 programs from 98 companies in 215 trials: 68 Phase 4, 66 Phase 2, 41 Phase 3, 40 Phase 1; Cardiovascular, Respiratory, Other; next expected readout Nov 2026.

G protein-coupled receptor for catecholamines that couples to both G(s) and G(i) proteins, activating bifurcated signaling pathways. ADRB2 binds epinephrine (Epi) with an approximately 30-fold greater affinity than norepinephrine (NE). (UniProt, P07550)

Open in Phaseline: the race on ADRB2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Yongtao SunEsmolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4FrailtyNov 2026
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
University of CalgaryCBD 100 mg OD
Interleukin-23 inhibitor
CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1Phase 4Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope …Dec 2026
King's College Hospital NHS TrustCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Cirrhosis, LiverDec 2026
Ottawa Heart Institute Research CorporationDobutamine
Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist
ADRB1, ADRB2Phase 4Shock, CardiogenicDec 2026
Cairo UniversityEphedrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Incidence of Post-spinal HypotensionDec 2026
Mansoura UniversityEphedrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Cesarean DeliveryDec 2026
Mansoura UniversityNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Cesarean DeliveryDec 2026
Dr. J. Alberto NederSalbutamol sulphate
Beta-2 adrenergic receptor agonist
ADRB2Phase 4COPDJan 2027
AstraZenecaAlbuterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 4AsthmaFeb 2027
University of North Carolina, Chapel HillPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Cardiovascular DiseaseFeb 2027
Sohag UniversityNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Patients Undergoing Orthopedic Hip Surgery Under Spinal AnesthesiaMar 2027
University of OklahomaPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Tobacco Use DisorderMar 2027
ARS PharmaceuticalsEpinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Allergic Reactions; Knee Arthroplasty, Total; Cardiac Arrest, Out-Of-Hospital; Shock Hypovolemic …Apr 2027
Icahn School of Medicine at Mount SinaiEphedrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4LaborMay 2027
Hospital Sirio-LibanesCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4CancerMay 2027
James J. Peters Veterans Affairs Medical CenterDroxidopa
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4HypotensionJun 2027
University of California, DavisNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Hypotension and ShockJun 2027
Aarhus University HospitalLabetalol
Adrenergic receptor antagonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Intracerebral HaemorrhageSep 2027
University of AlbertaNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4VasoconstrictionDec 2027
AstraZenecaBreztri Aerosphere
Triple combination: inhaled corticosteroid (budesonide) + long-acting muscarinic antagonis
ADRB2, CHRM3Phase 4Moderate to Severe COPDDec 2027
University Hospital, LimogesEsmolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Laparoscopic Cholecystectomy SurgeryJan 2028
University of MiamiAlbuterol-Budesonide (AIRSUPRA)
Fast-acting beta-2 agonist and inhaled corticosteroid combination
ADRB2, GRPhase 4AsthmaApr 2028
Chiesi FarmaceuticiFormoterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 4AsthmaJun 2028
Post Graduate Institute of Medical Education and Research, ChandigarhCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Cirrhotic CardiomyopathyJan 2029
Taipei Veterans General Hospital, TaiwanCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Hepatocellular Carcinoma (HCC); CirrhosisOct 2030
University of RochesterCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Heart Failure With Reduced Ejection Fraction (HFrEF)Jun 2031
Chinese University of Hong KongCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Portal HypertensionJul 2031
Bo Gregers WinkelNadolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Idiopathic Ventricular FibrillationDec 2032
Bo Gregers WinkelPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Idiopathic Ventricular FibrillationDec 2032
Bispebjerg HospitalCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Acute Myocardial InfarctionDec 2035
Bispebjerg HospitalNebivolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Acute Myocardial InfarctionDec 2035
Dalian Municipal Central HospitalEphedrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Hypotension Drug-Induced–
Nebraska Methodist Health SystemLabetalol
Adrenergic receptor antagonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Postpartum Preeclampsia–
Tunis UniversityNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Sepsis, Severe–
Dalian Municipal Central HospitalNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Hypotension Drug-Induced–
Hassan II UniversityNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Cesarean Section Complications–
Massachusetts General HospitalPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Stress Disorders, Post-Traumatic–
Walter Reed Army Institute of Research (WRAIR)Propranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Fear of Spiders–
University of Illinois ChicagoSotalol
Beta-1 adrenergic receptor antagonist; HERG blocker; Beta-2 adrenergic receptor antagonist
ADRB1, Ion channels, ADRB2Phase 4Atrial Fibrillation–
Federal University of São PauloTriplenex (triple fixed combination)
Triple combination: alpha-2 adrenergic agonist (brimonidine), non-selective beta-blocker (
ADRA2A, ADRB1, ADRB2, PTGFRPhase 4Glaucoma–
Beni-Suef UniversityVentoline® Evohaler® 100 µg/inhalation pMDI
Beta-2 adrenergic receptor agonist
ADRB2Phase 4Asthmatic Patients–
University of Texas Southwestern Medical Centerpropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Heat Stress–
NHS Greater Glasgow and ClydeNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3SepsisNov 2026
Mahidol UniversityVilanterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 3COPDDec 2026
Odense University HospitalNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3ShockDec 2026
Teva Branded Pharmaceutical Products R&DTEV-56248
Fixed-dose combination of inhaled corticosteroid (fluticasone propionate) and beta-2 agoni
ADRB2Phase 3AsthmaDec 2026
GSKFF/UMEC/VI
Inhaled corticosteroid/muscarinic antagonist/long-acting beta-2 agonist combination
CHRM3, ADRB2Phase 3AsthmaJan 2027
Consorcio Centro de Investigación Biomédica en Red (CIBER)Esmolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 3CirrhosisMar 2027
Jagiellonian UniversityNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3Blood Pressure ManagementJun 2027
Hospital do CoracaoNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3Septic ShockAug 2027
University Hospital, BordeauxNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3Stroke, AcuteAug 2027
University Hospital, ToulousePropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 3PTSDSep 2027
University of MonastirTerbutaline
Beta-2 adrenergic receptor agonist
ADRB2Phase 3Renal ColicDec 2027
AstraZenecaBGF MDI 320/14.4/9.6 μg
Triple therapy: inhaled corticosteroid (budesonide) + long-acting muscarinic antagonist (g
ADRB2, CHRM3Phase 3COPD (Chronic Obstructive Pulmonary Disease)Dec 2027
Loma Linda UniversityLabetalol
Adrenergic receptor antagonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3Postpartum ComplicationDec 2027
NovartisIndacaterol (QVM149)
Beta-2 adrenergic receptor agonist
ADRB2Phase 3AsthmaFeb 2028
Fundació d'investigació Sanitària de les Illes BalearsPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 3Traumatic Brain Injury (TBI) PatientsJun 2028
Lunan Better PharmaceuticalFormoterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 3Asthma (Diagnosis)Jun 2028
Chiesi FarmaceuticiCHF 5993 100/6/12.5 μg pMDI HFA-152a
Triple combination of inhaled corticosteroid, long-acting beta-2 agonist, and long-acting
ADRB2, CHRM3Phase 3AsthmaOct 2028
Acer TherapeuticsCeliprolol (ACER-002)
Beta-2 adrenergic receptor partial agonist; Adrenergic receptor alpha-2 antagonist; Beta-1 adrenergic receptor antagonist
ADRB2, ADRA2A, ADRA2C, ADRA2B, ADRB1Phase 3Vascular Ehlers-Danlos SyndromeMar 2029
SWOG Cancer Research NetworkCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 3CardiotoxicityJun 2031
Ain Shams UniversityCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 3Cardiotoxicity–
University of Turin, ItalyNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3Critical Illness–
Samsung Medical CenterVilanterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 3Chronic Obstructive Pulmonary Disease–
Emory UniversityPropranolol Hydrochloride
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Locally Advanced Bladder Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8Dec 2026
Medical University of South CarolinaFormoterol fumarate
Beta-2 adrenergic receptor agonist
ADRB2Phase 2Diabetic NephropathiesDec 2026
Stanford UniversityNebivolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Angina PectorisDec 2026
Morten Hostrup, PhDATR-258
GRK-selective long-acting β2-agonist
ADRB2Phase 2Overweight and ObesityDec 2026
Zealand University HospitalPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Pancreatic CancerDec 2026
Huashan Hospitalpropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Gastrointestinal TumorsDec 2026
Ain Shams UniversityNebivolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2HER2-positive Breast CancerFeb 2027
Assaf-Harofeh Medical CenterPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Colorectal NeoplasmsFeb 2027
Actimed TherapeuticsPindolol (ACM-001)
Beta-1 adrenergic receptor partial agonist; Beta-2 adrenergic receptor partial agonist
ADRB1, ADRB2Phase 2ObesityMar 2027
West China Hospitalpropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Infantile HemangiomaMar 2027
AHS Cancer Control AlbertaPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Pancreatic CancerMay 2027
Chiesi FarmaceuticiCHF5993 pMDI 100/6/12.5 µg with HFA-152a
Triple combination: inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA), long-
ADRB2, CRHR1Phase 2AsthmaJun 2027
Gianni SoraruClenbuterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 2Spinal and Bulbar Muscular AtrophyJun 2027
University of AarhusNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 2HypotensionDec 2027
Giuseppe Cullaro, MDDroxidopa
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 2Acute Kidney InjuryDec 2027
Niels JunkerPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Soft Tissue Sarcoma AdultJan 2028
University of VirginiaAnoro Ellipta
Long-acting muscarinic antagonist (umeclidinium) + long-acting beta-2 agonist (vilanterol)
CHRM3, ADRB2Phase 2Chronic Obstructive Pulmonary DiseaseJan 2028
AIDS Malignancy ConsortiumPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Kaposi SarcomaSep 2028
Jeremy Veenstra-vanderweelePropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Autism Spectrum DisorderNov 2028
University of ZurichPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Retinopathy of PrematurityDec 2028
Roswell Park Cancer InstitutePropranolol Hydrochloride
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Esophageal AdenocarcinomaMar 2029
University of AlbertaDobutamine
Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist
ADRB1, ADRB2Phase 2Hypoxic-ischemic Encephalopathy (HIE)Apr 2029
Sherief Abd-ElsalamCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 2Esophageal VaricesDec 2030
Michele Tagliati, MDCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 2REM Sleep Behavior Disorder–
Cedars-Sinai Medical CenterCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 2REM Sleep Behavior Disorder–
Copenhagen University Hospital, RigshospitaletDobutamine
Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist
ADRB1, ADRB2Phase 2Acute Myocardial Infarction–
St. John's Research InstituteNebivolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Diabetic Neuropathy Peripheral–
Tel-Aviv Sourasky Medical CenterPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Ovarian Cancer–
Kingston Health Sciences Centredobutamine
Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist
ADRB1, ADRB2Phase 2Shock–
Kingston Health Sciences Centrenorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 2Shock–
University of Colorado, DenverSalmeterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 1Altitude EdemaDec 2026
Geriatric Hospital of Nanjing Medical UniversityNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 1UrolithiasisDec 2026
PolareanAlbuterol Sulfate
Beta-2 adrenergic receptor agonist
ADRB2Phase 1Chronic Obstructive Pulmonary Disease; BronchiolitisDec 2026
University of Alabama at BirminghamLabetalol
Adrenergic receptor antagonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 1Hypertension in PregnancyDec 2026
Second Xiangya Hospital of Central South UniversityPropranolol hydrochloride
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1Non Small Cell Lung Cancer; Resectable Non-Small-Cell Lung Cancer; Small Cell Lung Cancer (SCLC)Dec 2026
EyeD PharmaTimolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1GlaucomaJan 2027
Icahn School of Medicine at Mount SinaiTimolol Maleate
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1Wound HealingJan 2027
GSKAlbuterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 1Asthma; TTN; LymphangioleiomyomatosisApr 2027
Steen Hvitfeldt PoulsenDobutamine
Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist
ADRB1, ADRB2Phase 1ATTR Amyloidosis Wild TypeSep 2027
Sarah WeissPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1Advanced MelanomaSep 2027
Jeffrey StatlandClenbuterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 1Muscular Dystrophy, FacioscapulohumeralFeb 2028
Instituto de Investigación Hospital Universitario La PazDobutamine
Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist
ADRB1, ADRB2Phase 1Infant, Premature, DiseasesJun 2029
Satish R. RajPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1TachycardiaDec 2029
Stephen G. KalerDroxidopa
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 1Menkes DiseaseJun 2030
Brigham and Women's HospitalNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 1Hypertension–
University Hospital, LilleTRIXEO AEROSPHERE (BGF 160)
Fixed triple combination: long-acting beta-2 agonist (formoterol), long-acting muscarinic
ADRB2, CHRM3, NR3C1Phase 1Copd–
Mansoura Universitycarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 1TBI Traumatic Brain Injury–
Mansoura Universitypropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1TBI Traumatic Brain Injury–

Conditions

Asthma (12) Shock (4) Acute Myocardial Infarction (3) Chronic Obstructive Pulmonary Disease (3) Nicotine Dependence (3) COPD (2) Pancreatic Cancer (2) Glaucoma (2) Cesarean Delivery (2) Cirrhosis (2) Hypotension (2) Cardiotoxicity (2)

Modalities

small molecule (100), mixed (8)

Companies

Mansoura University (4) Chiesi Farmaceutici (3) AstraZeneca (3) Icahn School of Medicine at Mount Sinai (2) Ain Shams University (2) University of Alberta (2) GSK (2) Dalian Municipal Central Hospital (2) Bispebjerg Hospital (2) Kingston Health Sciences Centre (2) Bo Gregers Winkel (2) Mahidol University (1) Zealand University Hospital (1) University of Oklahoma (1) Nebraska Methodist Health System (1) Copenhagen University Hospital, Rigshospitalet (1) Fundació d'investigació Sanitària de les Illes Balears (1) Federal University of São Paulo (1) Hospital do Coracao (1) Stanford University (1)

Related targets

ADRB1 (86) ADRA1A (42) ADRA2A (31) ADRA2C (30) ADRB3 (14) ADRA1D (13) CHRM3 (7) NR3C1 (3) IL12B (2) IL23A (2) HTR2A (2) PTGFR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.